ArticleEuropean urology oncology2024

Re: Bradley McGregor, Daniel M. Geynisman, Mauricio Burotto, et al. A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma. Eur Urol Oncol. 2023;6:339-348.

Juskaran Chadha et al.PubMed ↗Publisher ↗

No numbers read from the abstract.